Target
PIK3CA H1047R
6 abstracts
Abstract
Evaluation of genomic alterations in early-onset versus late-onset colorectal cancer.Org: Natera, Inc., Natera, Inc, Vanderbilt-Ingram Cancer Center,
Abstract
Ultra-sensitive, tumor-informed ctDNA profiling in patients with gastroesophageal cancer and treated with pembrolizumab and longitudinal ctDNA kinetics.Org: Duke University Medical Center, Personalis, Inc., University of North Carolina at Chapel Hill, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC).Org: Integrated Cancer Genomics Division, Translational Genomics Research Institute (TGen North), Phoenix, AZ, Translational Genomics Research Institute, Phoenix, AZ, Translational Genomics Research Institute (Phoenix, AZ),
Abstract
Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non-muscle invasive bladder cancer: A prospective study.Org: H. Lee Moffitt Cancer Center and Research Institute, Predicine, Inc., Predicine Inc., Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute,
Abstract
Frequency of somatic mutations in solid tumor malignancies from inner city minorities: A single center study.Org: John H. Stroger, Jr. Hospital of Cook County, Chicago, IL,